From this...

From this article:

http://www.businessspectator.com.au/bs.nsf/Article/Australias-Sigma-warns-on-sales-wins-debt-reprieve-D3VDQ?opendocument&src=rss

Shareholders of Sigma Pharmaceuticals Ltd have sent the debt-laden drugs maker into rehabilitation by approving the sale of its pharmaceuticals unit to relieve its $1.09 billion debt burden.

Chairman Brian Jamieson told shareholders the repayment of a $340 million syndicated debt facility due by September was the company's top priority, followed by repayments on $750 million worth of securitised debt due this March.

Sigma will be left with "a little debt...the extent of it is still to be determined", he told the meeting in Melbourne.
_____________________

The whole article provides more detail and context.

As to the sale not going through- it's a done deal. You can check out Aspen's lengthy submission to the ACCC as evidence of their commitment to quell the ACCC's concerns, and make certain guarantees to ensure competition remains sound. Aspen are in and there is no way they want out.